CY1123362T1 - Ανασυνδυασμενα ανυσματα hcmv και rhcmv εγκωδικευοντας ενα ετερολογο αντιγονο που απομονωνεται απο εναν ιο paramyxoviridae [παραμυξοϊοι] και χρησεις εξ' αυτων - Google Patents
Ανασυνδυασμενα ανυσματα hcmv και rhcmv εγκωδικευοντας ενα ετερολογο αντιγονο που απομονωνεται απο εναν ιο paramyxoviridae [παραμυξοϊοι] και χρησεις εξ' αυτωνInfo
- Publication number
- CY1123362T1 CY1123362T1 CY20201100816T CY201100816T CY1123362T1 CY 1123362 T1 CY1123362 T1 CY 1123362T1 CY 20201100816 T CY20201100816 T CY 20201100816T CY 201100816 T CY201100816 T CY 201100816T CY 1123362 T1 CY1123362 T1 CY 1123362T1
- Authority
- CY
- Cyprus
- Prior art keywords
- recombinant
- rhcmv
- vectors
- hcmv
- spread
- Prior art date
Links
- 241000701024 Human betaherpesvirus 5 Species 0.000 title abstract 6
- 239000013598 vector Substances 0.000 title abstract 6
- 239000000427 antigen Substances 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 241000711504 Paramyxoviridae Species 0.000 title 1
- 241000218605 Macacine betaherpesvirus 3 Species 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000037430 deletion Effects 0.000 abstract 2
- 238000012217 deletion Methods 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 230000028996 humoral immune response Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/869—Herpesviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- C07K14/16—HIV-1 ; HIV-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- C07K14/16—HIV-1 ; HIV-2
- C07K14/161—HIV-1 ; HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p7, p6, p66/68, p51/52, p31/34, p32, p40
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- C07K14/16—HIV-1 ; HIV-2
- C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- C07K14/16—HIV-1 ; HIV-2
- C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16161—Methods of inactivation or attenuation
- C12N2710/16162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Περιγράφονται εις το παρόν ανασυνδυασμένα ανύσματα κυτταρομεγαλοϊού «ρέζους» (RhCMV) και ανθρώπινου κυτταρομεγαλοϊού (HCMV) εγκωδικεύοντας ετερόλογα αντιγόνα, όπως είναι τα συγκεκριμένα για παθογόνα αντιγόνα ή τα αντιγόνα όγκων. Τα ανασυνδυασμένα ανύσματα εκμαιεύουν και διατηρούν υψηλού επιπέδου κυτταρικές και χυμικες ανοσιακές αποκρίσεις συγκεκριμένες για το ετερόλογο αντιγόνο. Τα ανασυνδυασμένα ανύσματα των RhCMV και HCMV μπορεί να χρησιμοποιηθούν, για παράδειγμα, για την αγωγή ή πρόληψη λοιμώδους πάθησης ή καρκίνου. Σε κάποια παραδείγματα, τα ανασυνδυασμένα ανύσματα των RhCMV ή HCMV μπορεί να συμπεριλάβουν απαλοιφές σε γονίδια εγκωδικεύοντας ανοσοδιαμορφωτικές πρωτεΐνες. Σε κάποια παραδείγματα, τα ανασυνδυασμένα ανύσματα των RhCMV ή HCMV μπορεί να είναι ανεπαρκή ή εξασθενημένα στη δυνατότητα των να αντιγραφούν στα πλαίσια ενός κυττάρου, να διασπαρθούν στα πλαίσια του ξενιστή ή να διαδοθούν μεταξύ ξενιστών από συμπερίληψη μιας απαλοιφής σε ένα ή περισσότερα γονίδια ουσιαστικά ή να επαυξήσουν αντιγραφή, διασπορά ή διάδοση του CMV.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33497610P | 2010-05-14 | 2010-05-14 | |
US37691110P | 2010-08-25 | 2010-08-25 | |
PCT/US2011/029930 WO2011119920A2 (en) | 2010-03-25 | 2011-03-25 | Cmv glycoproteins and recombinant vectors |
EP11781407.9A EP2569436B8 (en) | 2010-05-14 | 2011-05-16 | Recombinant hcmv and rhcmv vectors and uses thereof |
PCT/US2011/036657 WO2011143653A2 (en) | 2010-05-14 | 2011-05-16 | Recombinant hcmv and rhcmv vectors and uses thereof |
EP14162929.5A EP2772265B1 (en) | 2010-05-14 | 2011-05-16 | Recombinant HCMV and RHCMV vectors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123362T1 true CY1123362T1 (el) | 2021-12-31 |
Family
ID=44915020
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100226T CY1119944T1 (el) | 2010-05-14 | 2018-02-26 | Ανασυνδυασμενα ανυσματα των hcmv και rhcmv και χρησεις eξ' αυτων |
CY20181100413T CY1120464T1 (el) | 2010-05-14 | 2018-04-17 | Ανασυνδυασμενα ανυσματα των hcmv και rhcmv και χρησεις εξ' αυτων |
CY20201100410T CY1124015T1 (el) | 2010-05-14 | 2020-05-05 | Ανασυνδυασμενα ανυσματα hcmv και rhcmv εγκωδiκευοντας ενα ετερολογο αντιγονο που απομονωνεται απο ιο ηπατιτιδας β και χρησεις εξ αυτων |
CY20201100816T CY1123362T1 (el) | 2010-05-14 | 2020-09-01 | Ανασυνδυασμενα ανυσματα hcmv και rhcmv εγκωδικευοντας ενα ετερολογο αντιγονο που απομονωνεται απο εναν ιο paramyxoviridae [παραμυξοϊοι] και χρησεις εξ' αυτων |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181100226T CY1119944T1 (el) | 2010-05-14 | 2018-02-26 | Ανασυνδυασμενα ανυσματα των hcmv και rhcmv και χρησεις eξ' αυτων |
CY20181100413T CY1120464T1 (el) | 2010-05-14 | 2018-04-17 | Ανασυνδυασμενα ανυσματα των hcmv και rhcmv και χρησεις εξ' αυτων |
CY20201100410T CY1124015T1 (el) | 2010-05-14 | 2020-05-05 | Ανασυνδυασμενα ανυσματα hcmv και rhcmv εγκωδiκευοντας ενα ετερολογο αντιγονο που απομονωνεται απο ιο ηπατιτιδας β και χρησεις εξ αυτων |
Country Status (18)
Country | Link |
---|---|
US (3) | US9249427B2 (el) |
EP (5) | EP3739054A1 (el) |
AU (5) | AU2011252792C1 (el) |
CA (2) | CA3040225A1 (el) |
CY (4) | CY1119944T1 (el) |
DK (3) | DK2772265T3 (el) |
ES (4) | ES2819623T3 (el) |
HK (2) | HK1256651A1 (el) |
HR (4) | HRP20180267T1 (el) |
HU (4) | HUE050909T2 (el) |
LT (4) | LT3333265T (el) |
NO (2) | NO2772265T3 (el) |
PL (4) | PL2772265T3 (el) |
PT (3) | PT2569436T (el) |
RS (2) | RS56958B1 (el) |
SI (4) | SI3333265T1 (el) |
TR (1) | TR201802741T4 (el) |
WO (2) | WO2011143650A2 (el) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102844663B (zh) * | 2010-01-27 | 2016-01-06 | 俄勒冈健康科学大学 | 基于巨细胞病毒的免疫原性制剂 |
EP3187585A1 (en) * | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
LT3333265T (lt) * | 2010-05-14 | 2020-05-25 | Oregon Health & Science University | Rekombinantiniai žcmv ir rhcmv vektoriai, koduojantys heterologinį antigeną, išskirtą iš hepatito b viruso, ir jų panaudojimas |
EP2697248B1 (en) * | 2011-04-15 | 2020-03-11 | Nauclér, Cecilia | Genetic variant of cytomegalovirus (cmv) |
PL2691530T3 (pl) | 2011-06-10 | 2019-02-28 | Oregon Health & Science University | Glikoproteiny i rekombinowane wektory CMV |
CA2890061A1 (en) * | 2012-12-04 | 2014-06-12 | Merck Sharp & Dohme Corp. | Conditional replicating viral vectors |
AU2014207618A1 (en) | 2013-01-16 | 2015-08-06 | Emory University | Cas9-nucleic acid complexes and uses related thereto |
GB201301119D0 (en) * | 2013-01-22 | 2013-03-06 | Vaxxit Srl | Viral vaccines |
JP6483033B2 (ja) * | 2013-03-05 | 2019-03-13 | オレゴン・ヘルス・アンド・サイエンス・ユニバーシティOregon Health & Science University | T細胞ターゲティングを調節することができるサイトメガロウイルスベクター |
US20140335115A1 (en) * | 2013-05-07 | 2014-11-13 | Oregon Health & Science University | Suppressors of mature t cells |
EP3063274A4 (en) * | 2013-10-29 | 2017-04-05 | The University Of Sydney | Cmv immuno-stimulatory composition |
SG11201607287XA (en) | 2014-03-01 | 2016-09-29 | Univ Texas | Recombinant isfahan viral vectors |
MA39818A (fr) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
CN107002048B (zh) * | 2014-07-16 | 2021-07-06 | 俄勒冈健康与科学大学 | 包含外源抗原的人巨细胞病毒 |
MA40783A (fr) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
GB201501523D0 (en) * | 2015-01-30 | 2015-03-18 | Univ Plymouth | Differential immune response modulation |
EP3256595A4 (en) * | 2015-02-10 | 2018-09-26 | Oregon Health & Science University | Methods and compositions useful in generating non canonical cd8+ t cell responses |
US10117911B2 (en) | 2015-05-29 | 2018-11-06 | Agenovir Corporation | Compositions and methods to treat herpes simplex virus infections |
US20160346362A1 (en) * | 2015-05-29 | 2016-12-01 | Agenovir Corporation | Methods and compositions for treating cytomegalovirus infections |
GB201514034D0 (en) * | 2015-08-08 | 2015-09-23 | Univ Plymouth | Improvements in or relating to DNA recombination |
MA43285A (fr) * | 2015-11-20 | 2018-09-26 | Univ Oregon Health & Science | Vecteurs cmv comprenant des éléments de reconnaissance des microarn |
WO2017112797A1 (en) | 2015-12-22 | 2017-06-29 | Thomas Jefferson University | Intra-lesional cmv-based cancer vaccines |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
CA3028827A1 (en) | 2016-06-22 | 2017-12-28 | Aeras | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
EP3475446A1 (en) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
MX2019004518A (es) | 2016-10-18 | 2019-06-17 | Univ Oregon Health & Science | Vectores de citomegalovirus que provocan celulas t restringidas por moleculas del complejo mayor de histocompatibilidad e. |
US11638749B2 (en) | 2017-10-17 | 2023-05-02 | International Aids Vaccine Initiative, Inc. | Tuberculosis antigen cassettes |
WO2019173783A1 (en) * | 2018-03-09 | 2019-09-12 | The Regents Of The University Of California | Cmv vectors and uses thereof |
US20210047626A1 (en) | 2018-04-24 | 2021-02-18 | Merck Sharp & Dohme Corp. | Scalable chromatography process for purification of human cytomegalovirus |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
EP3905880A4 (en) | 2019-01-03 | 2022-10-05 | Merck Sharp & Dohme Corp. | SUPPLEMENTED SERUM CONTAINING CULTURE MEDIUM FOR ENHANCEMENT OF ARPE-19 GROWTH AND FOR THE PREPARATION OF A HUMAN CYTOMEGALOVIRUS VACCINE |
CN114025792A (zh) | 2019-03-21 | 2022-02-08 | 21C生物公司 | 针对感染期间的致病性免疫激活细胞的疫苗 |
US11077185B2 (en) | 2019-03-21 | 2021-08-03 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
US10632186B1 (en) | 2019-03-21 | 2020-04-28 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
US20220257740A1 (en) * | 2019-06-07 | 2022-08-18 | Oregon Health & Science University | Tumor-associated antigen-specific t cell responses |
TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白B(gB)多肽 |
CN117836311A (zh) * | 2021-08-31 | 2024-04-05 | 维尔生物科技公司 | 用于产生cmv载体的方法 |
KR20240049802A (ko) | 2021-08-31 | 2024-04-17 | 비르 바이오테크놀로지, 인코포레이티드 | 결핵 백신 |
AU2022339765A1 (en) | 2021-08-31 | 2024-01-25 | Vir Biotechnology, Inc. | Recombinant hcmv vectors and uses thereof |
WO2023059112A1 (ko) * | 2021-10-06 | 2023-04-13 | 주식회사 지앤피바이오사이언스 | 최적의 재조합 발현 구축물의 개발 |
WO2023133400A2 (en) * | 2022-01-07 | 2023-07-13 | Mayo Foundation For Medical Education And Research | Cytomegalovirus vectors and methods of use |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267965B1 (en) * | 1981-12-24 | 2001-07-31 | Virogenetics Corporation | Recombinant poxvirus—cytomegalovirus compositions and uses |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
WO1988010311A1 (en) | 1987-06-26 | 1988-12-29 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene and use thereof |
US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
EP1092775A1 (en) | 1991-07-05 | 2001-04-18 | American Cyanamid Company | Methods for identifiying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegalovirus |
WO1995003399A2 (en) * | 1993-07-19 | 1995-02-02 | Cantab Pharmaceuticals Research Limited | Production method for preparation of disabled viruses |
WO1995030019A1 (en) | 1994-04-29 | 1995-11-09 | Pharmacia & Upjohn Company | Feline immunodeficiency virus vaccine |
US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
EP0772619B2 (en) | 1994-07-15 | 2010-12-08 | The University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
JPH11500014A (ja) * | 1995-02-21 | 1999-01-06 | キャンタブ ファーマシューティカルズ リサーチ リミティド | ウイルス調製物、ベクター、免疫原、及びワクチン |
JPH11503024A (ja) | 1995-04-04 | 1999-03-23 | セル・ジェネシス・インコーポレイテッド | 細胞表面のクラスi mhcタンパク質の低レベルを有する遺伝子学的に修飾された細胞の移植 |
US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
ES2237800T3 (es) | 1996-07-31 | 2005-08-01 | Ortho-Mcneil Pharmaceutical, Inc. | Identificacion de genes del citomegalovirus humano implicados en la retro-regulacion de la expresion de las cadenas pesadas de la clase i del cmh. |
JP2001513776A (ja) | 1997-02-28 | 2001-09-04 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | LPS関連障害の処置における非メチル化CpGジヌクレオチドを含む核酸の使用 |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
AU7690898A (en) | 1997-05-20 | 1998-12-11 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
US20030138454A1 (en) * | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
DE19733364A1 (de) * | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
WO1999007869A1 (en) * | 1997-08-05 | 1999-02-18 | University Of Florida | Live recombinant vaccine comprising inefficiently or non-replicating virus |
JP2002510644A (ja) | 1998-04-03 | 2002-04-09 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物 |
US20020102536A1 (en) * | 1999-11-19 | 2002-08-01 | Xenova Research Limited | Preparation of human or animal herpesviruses |
US7204990B1 (en) * | 2000-11-28 | 2007-04-17 | Medimmune Vaccines, Inc. | Attenuation of cytomegalovirus virulence |
CA2437201C (en) * | 2001-02-02 | 2008-11-18 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
AU2002247733B2 (en) | 2001-02-21 | 2007-12-13 | The Wistar Institute Of Anatomy And Biology | Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
GB0122232D0 (en) * | 2001-09-14 | 2001-11-07 | Medical Res Council | Gene expression |
AU2002362368B2 (en) * | 2001-09-20 | 2006-09-21 | Glaxo Group Limited | HIV-gag codon-optimised DNA vaccines |
SG2013034475A (en) * | 2001-11-21 | 2016-10-28 | Univ Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
US20030118568A1 (en) | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
CN100471957C (zh) * | 2002-04-30 | 2009-03-25 | 艾维亚医药/生物技术有限公司 | 用于免疫治疗的腺病毒载体 |
CA2484669A1 (en) * | 2002-05-08 | 2003-11-20 | Akzo Nobel N.V. | Brachyspira hyodysenteriae vaccine |
DE10232322A1 (de) | 2002-07-16 | 2004-07-29 | Hahn, Gabriele, Dr. | Viral kodierte CxC determinieren den Gewebetropismus von HCMV |
WO2005012545A2 (en) * | 2003-07-25 | 2005-02-10 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors |
EP1766096B1 (en) | 2004-05-25 | 2013-01-02 | Oregon Health and Science University | Hiv vaccination usingand hcmv-based vaccine vectors |
EP1602676A1 (en) | 2004-06-01 | 2005-12-07 | SOLVAY (Société Anonyme) | Catalytic compositions |
EP1799255A4 (en) * | 2004-06-25 | 2008-10-01 | Medimmune Vaccines Inc | RECOMBINANT HUMANESE CYTOMEGALOVIRUS AND HETEROLOGIST ANTIGENS CONTAINING VACCINES |
US8668564B2 (en) | 2005-01-24 | 2014-03-11 | Solution Champion Limited | Jackpot method and system |
EP1888622A1 (en) * | 2005-05-23 | 2008-02-20 | Oxxon Therapeutics Ltd. | Compositions for inducing an immune response against hepatitis b |
CA2620495A1 (en) * | 2005-08-31 | 2007-03-08 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
JP5349049B2 (ja) | 2005-10-17 | 2013-11-20 | メディミューン,エルエルシー | インフルエンザウイルス製造用マルチプラスミド系 |
WO2008112146A2 (en) | 2007-03-07 | 2008-09-18 | The Trustees Of The University Of Pennsylvania | 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction |
AU2008287195A1 (en) | 2007-07-06 | 2009-02-19 | Emergent Product Development Seattle, Llc | Binding peptides having a C-terminally disposed specific binding domain |
PT2215117E (pt) | 2007-10-30 | 2015-04-01 | Genentech Inc | Purificação de anticorpo por cromatografia de troca de catiões |
JP2012519484A (ja) | 2009-03-06 | 2012-08-30 | マウント・シナイ・スクール・オヴ・メディシン | マイクロrna応答要素を含む弱毒化生インフルエンザウイルスワクチン |
ES2786039T3 (es) | 2009-04-30 | 2020-10-08 | Ospedale San Raffaele Srl | Vector génico |
BR112012015523A2 (pt) | 2009-12-23 | 2017-04-18 | 4-Antibody Ag | membros de ligação do citomegalovirus humano, composição contendo os mesmos, método de tratamento, moléculas de anticorpo, método de produção, molecular de ácido nucléico, célula hospedeira, e, método de neutralização do hcmv. |
CN102844663B (zh) | 2010-01-27 | 2016-01-06 | 俄勒冈健康科学大学 | 基于巨细胞病毒的免疫原性制剂 |
EP3187585A1 (en) * | 2010-03-25 | 2017-07-05 | Oregon Health&Science University | Cmv glycoproteins and recombinant vectors |
CA2798214C (en) | 2010-05-05 | 2021-10-19 | Christian Thirion | Vaccine against beta-herpesvirus infection and use thereof |
LT3333265T (lt) | 2010-05-14 | 2020-05-25 | Oregon Health & Science University | Rekombinantiniai žcmv ir rhcmv vektoriai, koduojantys heterologinį antigeną, išskirtą iš hepatito b viruso, ir jų panaudojimas |
PL2691530T3 (pl) | 2011-06-10 | 2019-02-28 | Oregon Health & Science University | Glikoproteiny i rekombinowane wektory CMV |
US20140227708A1 (en) | 2011-09-16 | 2014-08-14 | Oregon Health & Science University | Methods and kits used in identifying microrna targets |
US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
JP6483033B2 (ja) | 2013-03-05 | 2019-03-13 | オレゴン・ヘルス・アンド・サイエンス・ユニバーシティOregon Health & Science University | T細胞ターゲティングを調節することができるサイトメガロウイルスベクター |
CN107002048B (zh) | 2014-07-16 | 2021-07-06 | 俄勒冈健康与科学大学 | 包含外源抗原的人巨细胞病毒 |
EP3048114A1 (en) * | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
EP3256595A4 (en) | 2015-02-10 | 2018-09-26 | Oregon Health & Science University | Methods and compositions useful in generating non canonical cd8+ t cell responses |
MA43285A (fr) | 2015-11-20 | 2018-09-26 | Univ Oregon Health & Science | Vecteurs cmv comprenant des éléments de reconnaissance des microarn |
CA3028827A1 (en) | 2016-06-22 | 2017-12-28 | Aeras | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
EP3475446A1 (en) | 2016-06-27 | 2019-05-01 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
MX2019004518A (es) | 2016-10-18 | 2019-06-17 | Univ Oregon Health & Science | Vectores de citomegalovirus que provocan celulas t restringidas por moleculas del complejo mayor de histocompatibilidad e. |
-
2011
- 2011-05-16 LT LTEP17197412.4T patent/LT3333265T/lt unknown
- 2011-05-16 SI SI201131872T patent/SI3333265T1/sl unknown
- 2011-05-16 WO PCT/US2011/036628 patent/WO2011143650A2/en active Application Filing
- 2011-05-16 ES ES17205199T patent/ES2819623T3/es active Active
- 2011-05-16 LT LTEP14162929.5T patent/LT2772265T/lt unknown
- 2011-05-16 PL PL14162929T patent/PL2772265T3/pl unknown
- 2011-05-16 PT PT117814079T patent/PT2569436T/pt unknown
- 2011-05-16 NO NO14162929A patent/NO2772265T3/no unknown
- 2011-05-16 EP EP20155440.9A patent/EP3739054A1/en active Pending
- 2011-05-16 PL PL17205199T patent/PL3351636T3/pl unknown
- 2011-05-16 SI SI201131428T patent/SI2569436T1/en unknown
- 2011-05-16 RS RS20180219A patent/RS56958B1/sr unknown
- 2011-05-16 DK DK14162929.5T patent/DK2772265T3/en active
- 2011-05-16 EP EP17197412.4A patent/EP3333265B1/en active Active
- 2011-05-16 ES ES17197412T patent/ES2788198T3/es active Active
- 2011-05-16 PT PT172051997T patent/PT3351636T/pt unknown
- 2011-05-16 HU HUE17205199A patent/HUE050909T2/hu unknown
- 2011-05-16 CA CA3040225A patent/CA3040225A1/en active Pending
- 2011-05-16 ES ES11781407.9T patent/ES2660615T3/es active Active
- 2011-05-16 DK DK17197412.4T patent/DK3333265T3/da active
- 2011-05-16 HU HUE11781407A patent/HUE036122T2/hu unknown
- 2011-05-16 NO NO11781407A patent/NO2569436T3/no unknown
- 2011-05-16 SI SI201131464T patent/SI2772265T1/en unknown
- 2011-05-16 DK DK11781407.9T patent/DK2569436T3/en active
- 2011-05-16 LT LTEP17205199.7T patent/LT3351636T/lt unknown
- 2011-05-16 PL PL11781407T patent/PL2569436T3/pl unknown
- 2011-05-16 TR TR2018/02741T patent/TR201802741T4/tr unknown
- 2011-05-16 PL PL17197412T patent/PL3333265T3/pl unknown
- 2011-05-16 AU AU2011252792A patent/AU2011252792C1/en active Active
- 2011-05-16 ES ES14162929.5T patent/ES2666043T3/es active Active
- 2011-05-16 CA CA2798136A patent/CA2798136C/en active Active
- 2011-05-16 EP EP14162929.5A patent/EP2772265B1/en active Active
- 2011-05-16 WO PCT/US2011/036657 patent/WO2011143653A2/en active Application Filing
- 2011-05-16 PT PT141629295T patent/PT2772265T/pt unknown
- 2011-05-16 HU HUE17197412A patent/HUE049725T2/hu unknown
- 2011-05-16 SI SI201131912T patent/SI3351636T1/sl unknown
- 2011-05-16 HU HUE14162929A patent/HUE037227T2/hu unknown
- 2011-05-16 EP EP17205199.7A patent/EP3351636B1/en active Active
- 2011-05-16 LT LTEP11781407.9T patent/LT2569436T/lt unknown
- 2011-05-16 EP EP11781407.9A patent/EP2569436B8/en active Active
- 2011-05-16 RS RS20180444A patent/RS57274B1/sr unknown
-
2012
- 2012-11-14 US US13/694,280 patent/US9249427B2/en active Active
-
2015
- 2015-10-01 US US14/872,756 patent/US9982241B2/en active Active
-
2016
- 2016-03-23 AU AU2016201853A patent/AU2016201853A1/en not_active Abandoned
-
2018
- 2018-02-13 HR HRP20180267TT patent/HRP20180267T1/hr unknown
- 2018-02-26 CY CY20181100226T patent/CY1119944T1/el unknown
- 2018-04-16 HR HRP20180601TT patent/HRP20180601T1/hr unknown
- 2018-04-17 CY CY20181100413T patent/CY1120464T1/el unknown
- 2018-04-27 US US15/965,246 patent/US11266732B2/en active Active
- 2018-05-09 AU AU2018203259A patent/AU2018203259A1/en not_active Abandoned
- 2018-12-10 HK HK18115806.2A patent/HK1256651A1/zh unknown
- 2018-12-18 HK HK18116180.6A patent/HK1257045A1/zh unknown
-
2019
- 2019-07-11 AU AU2019204982A patent/AU2019204982B2/en active Active
-
2020
- 2020-04-30 HR HRP20200698TT patent/HRP20200698T1/hr unknown
- 2020-05-05 CY CY20201100410T patent/CY1124015T1/el unknown
- 2020-09-01 CY CY20201100816T patent/CY1123362T1/el unknown
- 2020-09-03 HR HRP20201406TT patent/HRP20201406T1/hr unknown
-
2022
- 2022-02-22 AU AU2022201186A patent/AU2022201186A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123362T1 (el) | Ανασυνδυασμενα ανυσματα hcmv και rhcmv εγκωδικευοντας ενα ετερολογο αντιγονο που απομονωνεται απο εναν ιο paramyxoviridae [παραμυξοϊοι] και χρησεις εξ' αυτων | |
CY1120987T1 (el) | Cmv γλυκοπρωτεϊνες και ανασυνδυασμενοι φορεις | |
CY1122790T1 (el) | Αντι-ανθρωπινου ιου των θηλωματων 16 ε7 τ κυτταρου υποδοχεις | |
EA201400912A1 (ru) | Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе | |
ATE528016T1 (de) | Virusähnliche partikel als paramyxovirus- impfstoffe | |
CY1110585T1 (el) | ΣΥΣΚΕΥΑΣΙΑ (ΠΑΚΕΤΑΡΙΣΜΑ) ΑΝΟΣΟΔΙΕΓΕΡΤIΚΩΝ CpG ΕΝΤΟΣ ΟΜΟΙΑΖΟΝΤΩΝ ΜΕ ΙΟ ΣΩΜΑΤΙΩΝ: ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΚΑΙ ΧΡΗΣΗ | |
MX352974B (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
BR112015021945A8 (pt) | vetores de citomegalovírus humanos ou animais e seus usos | |
CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
EA202090759A2 (ru) | Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина | |
MX2019000215A (es) | Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso. | |
BRPI0816134A2 (pt) | Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença. | |
WO2005092374A3 (en) | Recombinant herpes simplex virus and uses therefor | |
Hodgins et al. | A plant-derived VLP influenza vaccine elicits a balanced immune response even in very old mice with co-morbidities | |
MY184576A (en) | Recombinant proteins and their therapeutic uses | |
CY1118573T1 (el) | Χρηση ενος τροποποιημενου ιου ευλογιας για την ταχεια επαγωγη ανοσιας εναντι ενος ιου ευλογιας ή αλλων μολυσματικων παραγοντων | |
CY1124707T1 (el) | Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων) | |
MX2016014868A (es) | Metodos para secar por congelacion y rehidratar productos biologicos. | |
CY1125328T1 (el) | Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων | |
WO2012038832A3 (en) | Generation of replicating chimeric measles virus - retrovirus particles | |
ATE494377T1 (de) | Vakzine gegen ipnv die aus hefezellen isoliert werden | |
DE60239753D1 (de) | Impfstoff gegen infektiöses lachsanämievirus | |
Fu et al. | Evaluation of the enhancing ability of three adjuvants for DNA vaccination using the porcine circovirus type 2 ORF2 (capsid) gene in mice | |
MX2019006245A (es) | Construcciones de vectores virales para la expresion de adyuvantes geneticos que activan las rutas cd40 y sting. | |
Golshani et al. | A RECOMBINANT SUBUNIT VACCINE BASED ON THE L7/L12 AND TOMP31 PROTEINS INDUCES PROTECTION AGAINST BRUCELLA INFECTION IN BALB/C MICE |